Category: Pay-for-Delay

Pay For Delay Drug Litigation

Pay-for-Delay Lawsuits Strengthened by CA Supreme Court Opinion

Audet & Partners, LLP reports that the California Supreme Court has issued an opinion which may leave large pharmaceutical companies vulnerable to antitrust challenges arising out of patent litigation settlements that effectively stifle competition in the[...]

Pay-for-Delay Lawsuit re Opana

Pay-for-Delay Lawsuit Alleges Scheme Against Generic Opana Painkiller

Audet & Partners, LLP reports that a lawsuit has been brought in an Illinois federal court on behalf of an employee trust fund alleging an illegal scheme to deprive the market of generic Opana ER, an extended-release[...]

Pay for Delay Nexium Lawsuit

Pay-for-Delay Lawsuit Involving Nexium Reopened by Federal Court

In the Nexium pay-for-delay multidistrict litigation accusing drug companies of violating antitrust laws by agreeing to delay entry of a generic version of AstraZenca’s heartburn drug Nexium, federal Judge William Young may be reconsidering some of[...]

Pay for Delay Drug Costs

Pay-for-Delay Tactics of Drug Manufacturers Considered by Supreme Court

The debate over "reverse payment" patent litigation settlements continues following the Supreme Court's decision in FTC v. Actavis that such agreements should be individually evaluated to determine whether they violate the anti-trust laws. Reverse payment settlements[...]